Comprehensive proteogenomic characterization reveals clinically relevant molecular subtypes associated with medulloblastoma progression.
Park SM, Kim KH, Yoon JH, D'Angelo F, Choi SA, Kim CI, Koo H, Park S, Kim H, Sundara Raj S, Kim SS, Park AK, Koh EJ, Kim SI, Shim YM, Kwang-Hoon L, Kim EE, Phi JH, Jo YS, Nam DH, Hwang D, Hyeon DY, Huh S, Kwon HJ, Ha S, Park S, Shin H, Kwon JT, Yoo H, Gwak HS, D Taylor M, Park BJ, Sa JK, Kim Y, Iavarone A, Park SH, Kim SK, Park JB.
Park SM, et al.
Exp Mol Med. 2026 Jun;58(6):1885-1899. doi: 10.1038/s12276-026-01732-0. Epub 2026 Jun 5.
Exp Mol Med. 2026.
PMID: 42249086
Free PMC article.